// App-Quantinova.ai

e11513 : Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine is a very effective and well-tolerated regimen (CLT) in metastatic HER2-positive breast cancer patients.

Researchers

Presenter

  • Jose E. Ales-Martnez

Principal Investigators

  • Elena Filipovich

  • Juan Luis Garca Llano

  • Jaime Ceballos Viro

  • Ricardo Snchez-Escribano

Medical Centers

  • Complejo Asistencial de Segovia, Segovia, Spain

  • Complejo Asistencial de Burgos, Burgos, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Proliferation marker protein Ki-67

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Capecitabine

  • Trastuzumab

  • Lapatinib

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved